EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database

Lori D. Bash, Tun-Ying Hsu, Vasilisa Sazonov, Baishali Ambegaonkar

World Journal of Cardiovascular Diseases · 2012

DOI: 10.4236/wjcd.2012.22011 ↗

At a glance

Journal article in World Journal of Cardiovascular Diseases, 2012. Written by Lori D. Bash and 3 co-authors. 30 references. The full text is freely available (open access, CC BY 4.0).

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Dyslipidemia, including low levels of high-density lipoprotein cholesterol (HDL-C), is a relatively well-established risk factor for cardiovascular disease. However, the independent association between changes in HDL-C and the subsequent risk of cardiovascular events has not been well studied. The retrospective cohort analysis was conducted to evaluate the association between changes in HDL-C and cardiovascular (CV) and/or cerebrovascular (CB) events among statin-treated patients. Patient demo-graphics, clinical characteristics, laboratory data, and CV/CB events, were collected from the UK General Practice Research Database. The association between the risk of an incident event and changes in patients’ HDL-C was estimated using multivariate Cox pro-portional hazards models. Among 17,923 statin-treated patients with an average follow-up of 1.9 years, there were 815 CV events and 220 CB events. The average change in HDL-C experienced was 0.4 mg/dL, ranging from 11 mg/dL average decrease in the lowest change quartile to 12 mg/dL average increase in the highest change quartile. CV events occurred at an average overall rate of 21 per 1000 person-years and 17 per 1000 person-years among individuals in the highest quartile of change in HDL-C levels. Fully adjusted Cox regression estimated a 6% decrease in hazards (HR, 0.94; 95% CI, 0.90, 0.98) of a subsequent CV event associated with each 5 mg/dL increase in HDL-C. Similar results (HR: 0.95, 95% CI, 0.92, 0.98) were observed when assessing the association with changes in HDL-C and the composite outcome of CV/CB event. Among statin-treated patients from UK clinical practices, increases in HDL-C were associated with a significantly decreased relative risk of experiencing CV/CB events with a more pronounced effect on CV events. Therefore, a more aggressive treatment to increase HDL-C could benefit patients by reducing the risk of CV/CB events.

Cite

APA

Bash, L. D., Hsu, T., Sazonov, V., & Ambegaonkar, B. (2012). Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database. World Journal of Cardiovascular Diseases. https://doi.org/10.4236/wjcd.2012.22011

Vancouver

Bash LD, Hsu T, Sazonov V, Ambegaonkar B. Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database. World Journal of Cardiovascular Diseases. 2012. doi:10.4236/wjcd.2012.22011

BibTeX
@article{Bash2012,
  author = {Bash, Lori D. and Hsu, Tun-Ying and Sazonov, Vasilisa and Ambegaonkar, Baishali},
  title = {Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database},
  journal = {World Journal of Cardiovascular Diseases},
  year = {2012},
  doi = {10.4236/wjcd.2012.22011}
}
Start for free →